| Identification | Back Directory | [Name]
Samidorphan | [CAS]
852626-89-2 | [Synonyms]
Morphinan-3-carboxamide, 17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxo- | [Molecular Formula]
C21H26N2O4 | [MOL File]
852626-89-2.mol | [Molecular Weight]
370.44 |
| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to yellow | [InChIKey]
RYIDHLJADOKWFM-MAODMQOUSA-N | [SMILES]
C1=C2C([C@]34CCN(CC5CC5)[C@H](C2)[C@]3(O)CCC(=O)C4)=C(O)C(C(N)=O)=C1 |
| Hazard Information | Back Directory | [Uses]
Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo[1]. | [Definition]
ChEBI:Samidorphan is a member of phenanthrenes. | [References]
[1] McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46(3):239-45. DOI:10.1002/eat.22114
[2] Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond). 2022 Jun 30;79:104115. DOI:10.1016/j.amsu.2022.104115
[3] Mark S. Todtenkopf, et al. Buprenorphine in Combination with Samidorphan (ALKS 33) Results in Antidepressive-Like Effects in Two Distinct Rat Models. Eur Neuropsychopharmacol. 2014;24aSuppl 2):S366. |
|
| Company Name: |
Lewens Labs
|
| Tel: |
+917043057100 |
| Website: |
www.lewenslabs.com |
|